What is Wellumio?
Wellumio is a specialized medical device developer focused on revolutionizing acute stroke diagnosis through advanced neuroimaging technology. Its flagship innovation, Axana, utilizes a proprietary Pulsed Gradient Free Mapping (PGFM) method to identify brain tissue affected by stroke with unprecedented speed and accuracy. By bypassing the logistical constraints of traditional, stationary MRI systems, Wellumio provides clinicians with the ability to perform rapid, point-of-care assessments in acute care environments. This capability is essential for facilitating earlier clinical decision-making, which is a primary determinant in improving long-term patient outcomes. The company occupies a vital niche in the MedTech landscape, bridging the gap between complex diagnostic requirements and the practical needs of emergency medical settings.
How much funding has Wellumio raised?
Wellumio has raised a total of $14.1M across 2 funding rounds:
Seed
$4.3M
Other Financing Round
$9.8M
Seed (2023): $4.4M, investors not publicly disclosed
Other Financing Round (2026): $9.8M led by Icehouse Ventures, The NZGCP, Flying Kiwi Angels, Booster, Cure Kids, Bioshore Ventures, Pacific Channel, Nuance Capital, and Enterprise Angels
Key Investors in Wellumio
Icehouse Ventures
A prominent New Zealand-based early-stage venture firm managing significant assets, dedicated to supporting Kiwi innovators with a vast network of co-investors.
The NZGCP
A government-backed investment entity providing critical support to New Zealand technology companies through seed and venture capital funds.
Bioshore Ventures
An investment firm specializing in medical technology, focused on driving clinical and commercial outcomes for early-stage biotech and MedTech enterprises.
What's next for Wellumio?
With the successful closure of this major strategic investment, Wellumio is poised to scale its operational capacity and accelerate the commercialization of the Axana platform. The company's strategic roadmap focuses on deepening its clinical evidence base and expanding its footprint within international healthcare systems. By leveraging the expertise of its diverse investor base, Wellumio aims to refine its manufacturing processes and navigate the regulatory pathways necessary for global adoption. As the firm moves into this next phase of growth, the focus will remain on enhancing the accessibility of its neuroimaging technology, ultimately aiming to set a new standard for stroke care and diagnostic efficiency in hospitals worldwide.
See full Wellumio company page
